Tirzepatide delivers superior 12-month weight loss (16.6% TBWL) over semaglutide with fewer GI side effects in real-world obesity patients.
Background
Despite the efficacy of GLP-1 receptor agonists for obesity and type 2 diabetes, real-world data directly comparing newer agents like tirzepatide and semaglutide are crucial for clinical decision-making. Head-to-head trials are often limited, leaving gaps in understanding comparative effectiveness and safety in diverse patient populations, especially those with prior experience with other anti-obesity medications. This study addresses the need for practical insights into how these powerful incretin mimetics perform in routine clinical practice.
Study Design
This retrospective, multicenter study analyzed 511 adults prescribed tirzepatide (n=207) or semaglutide (n=304) for weight loss across multiple US healthcare centers from January 2021 to May 2024. The primary endpoint was total body weight loss percentage (TBWL%) assessed at 3, 6, 9, and 12 months. Subgroup analyses examined outcomes by diabetes status, medication dose, and prior obesity medication (OM) use. Safety was evaluated based on reported gastrointestinal side effects.
Results
Among 511 patients (mean BMI 40.0 kg/m2), tirzepatide was associated with significantly greater 12-month TBWL% than semaglutide (16.6% ± 8.6% vs 13.4% ± 8.0%; P<.01). This difference was particularly pronounced in patients without diabetes, where tirzepatide led to 18.5% ± 8.2% TBWL% compared to semaglutide's 14.2% ± 8.6% (P<.01). Prior OM use reduced weight loss in both groups, but tirzepatide still showed a greater effect (16.1% vs 17.1% for prior vs. no prior OM, P<.01).
Key Findings
- Tirzepatide users achieved 16.6% ± 8.6% total body weight loss (
TBWL%) at 12 months, significantly more than semaglutide users (13.4% ± 8.0%; P<.01). - More tirzepatide users achieved ≥15%
TBWL%(56.8% vs 40.7%; P=.03) and ≥20%TBWL%(39.0% vs 22.1%; P<.01). - In patients without diabetes, tirzepatide led to 18.5% ± 8.2%
TBWL%vs. semaglutide's 14.2% ± 8.6% (P<.01). - Semaglutide users reported significantly more gastrointestinal side effects (50.7%) than tirzepatide users (28.5%; P<.01).
- Prior obesity medication use reduced weight loss in both groups, but tirzepatide maintained a superior effect.
Why It Matters
This real-world data provides strong evidence that tirzepatide offers superior weight loss efficacy compared to semaglutide, even in patients with previous anti-obesity medication exposure. For clinicians and individuals seeking maximal weight loss, particularly those without diabetes, tirzepatide may be the preferred option. The finding of fewer gastrointestinal side effects with tirzepatide is also a significant practical consideration, potentially improving adherence and tolerability for many users. This study helps inform prescribing decisions and patient expectations, suggesting that a tirzepatide-based protocol could yield greater results with potentially fewer GI issues.
obesity
tirzepatide
semaglutide
weight-loss
glp-1-agonist
gip-agonist